hepatitis meds Flashcards
Causes of Hepatitis
- viral hepatitis
- alcoholic hepatitis
- toxic&drug induced hepatitis
- autoimmune
- nonalcoholic fatty liver disease
- ischemic hepatitis
- giant cell hepatitis
Which types of viral hepatitis are acute only?
A & E
Which types of viral hepatitis are fecal-oral transmission?
A & E
Hepatitis A Virus
-
transmission: fecal-oral
- close-personal contact
- blood exposure (rare)
-
Incubation:
- approx 30 days; 4 weeks; 1 month
-
Detection of acute infx:
- HAV-IgM antibodies in serum
-
Detection of immunity:
- serum HAV-IgG
-
Detecting HAV RNA:
- RT-PCR: reverse transcriptase PCR
- No tx → supportive care (nearly all recover within 6 months)
HAV Prevention
promote proper sanitary practice
frequent hand washing
safe food prep
HAV Prevention - Immune Globulin
-
Passive immunization:
- IM polyclonal serum immune globulin
- we administer antibody into the person
- body does not amount an immune response, it just gets immunity
- IM polyclonal serum immune globulin
-
Pre-exposure:
- at least 14 days before exposure
- travelers to intermediate and high HAV-endemic regions
- <3 months: 0.02mL/Kg
- ≥ 3 months: 0.06mL/Kg (q4-6mo)
-
Post-Exposure:
- within 14 days of exposure
- household or other intimate contacts
- 0.02mL/kg
- institutions
- common source exposure (i.e. food made by infected person)
Who should be vaccinated against HAV?
children > 1 yr
persons who are at risk for infx or complications
- Adults should receive 2 dose series at least 2 weeks prior to expected HAV exposure
- different vaccine, not immunoglobulin
- these are antigen-initiated immune responses
- VAQTA & HAVARIX = hep A only
- VAQTA: <18: 25 units, ≥ 19: 50 units
- HAVARIX: ≤ 18: 720 units, ≥ 19: 1550 units
- TWINRIX = Hep A & B
-
only ≥ 18: 720U/20mcg (HBsAg)
- 3 dose: 0, 1, 6
- 4 dose: 0, 7d, 21-30d, 12 months
-
only ≥ 18: 720U/20mcg (HBsAg)
Hepatitis B Virus
dsDNA
surface antigen, core antigen, E antigen
-
Transmission: vertical transmission is most common in high prevalence areas
- close contact (children) in intermediate prevalence areas
- unprotected Sex & IV drug use in adults in low prevalence areas
- incubation: ~60-90 days, 2-3 months
-
Acute infx:
- HBsAg
-
Viral replication:
- HBeAg
- demonstrates active & rapid viral replication
- HBeAg
-
Active infx, viral replication:
- HBV DNA
- guides management of chronic infx
- HBV DNA
-
Immunity to infx:
- Anti-HBs
-
inactive infx:
- Anti-HBe
-
Resolution of infx:
- Anti-HBc
- immunized pts do not produce Anti-HBc
- Anti-HBc
HBV immune tolerant phase
HBeAG (+)
Viral load > 20K IU/mL
ALT/AST relatively normal
HBV Immune Active Phase
HBeAg (+)
→ virus is replicating
elevated viral load & ALT/AST
HBV Inactive chronic hepatitis B Phase
- Viral load = low or undetectable <2K
- ALT/AST normal
- HBeAG (-)
- virus not replicating
- Anti-HBe present
HBV Immune Reactivation Phase
- HBeAg (-)
- virus not replicating
- increased VL & AST/ALT
- among those who seroconvert from HBeAG (+) to Anti-HBe → 10-30% will continue to have high ALT/AST & viral loads
Normal ALT levels for men & women
- men: < 30U/L
- women: <19 U/L
When to tx: HBeAg Positive: ALT≤ ULN, ALT > ULN but <2x ULN, ALT ≥ ULN
When to Tx: HBeAg negative, ALT ≤ ULN, ALT > ULN but < 2x ULN, ALT ≥ 2x ULN
Tenofovir, TDF
used for HBV
prodrug
- Preferred in pregnancy
- do not D/C abruptly
-
caution in HIV/HBV co-infected patients
- ritonavir (HIV antiretroviral therapy) will boost levels of tenofovir
- Renal dose adjustments when CrCl ≤ 50mL/min
- does not last as long as tenofovir alafenamide
-
SEs:
-
Fanconi syndrome:
- kidney tubule disorder, excrete glucose, bicarb, phosphate, K+, amino acids
- should add a CMP + phosphorus
- kidney tubule disorder, excrete glucose, bicarb, phosphate, K+, amino acids
- Osteomalacia and decreased bone density
-
Fanconi syndrome:
Tenofovir alafenamide, TAF
- prodrug of tenofovir
- Not for CrCl < 15mL/min
- more stable in plasma → less renal/bone toxicity
-
SEs:
- lactic acidosis
*
- lactic acidosis